Julie Collins

Julie Collins

Auto-generated profile, based on publicly available information

Julie Collins

Medstar Georgetown University Hospital, Washington, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
JCJulie M. Collins
Julie M. Collins
JGJames L. Gulley
James L. Gulley
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor microenvironment and reducing tumor growth. Most early clinical trials of avelumab as monotherapy and in combination regimens were part of the international JAVELIN clinical trial program, which included more than 7000 patients in more than 30 trials with at least 15 tumor types. Avelumab has been approved by the U.S. FDA for the treatment of metastatic Merkel cell carcinoma and metastatic urothelial carcinoma that has progressed during or following treatment with a platinum-based regimen. Its acceptable safety profile and ability to induce durable responses in otherwise deadly tumors provide the rationale for its use in other tumor types and in combination with other therapies.

27 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
FLFilipa Lynce
Filipa Lynce
CMCandace Mainor
Candace Mainor
RDRenee N. Donahue
Renee N. Donahue
XGXue Geng
Xue Geng
GJGreg Jones
Greg Jones
CIClaudine Isaacs
Claudine Isaacs
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) is associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.

18 April 2013 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
JCJulie M. Collins
Julie M. Collins
KHKevin Haynes
Kevin Haynes
JGJason C. Gallagher
Jason C. Gallagher

11 July 2020 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
JCJulie M. Collins
Julie M. Collins
CIClaudine Isaacs
Claudine Isaacs

13 March 2023 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
TRTina Roy
Tina Roy
EBElizabeth Barrows
Elizabeth Barrows
CMCandace Mainor
Candace Mainor
JCJulie Collins
Julie Collins
FLFilipa Lynce
Filipa Lynce
PPPaula R Pohlmann
Paula R Pohlmann
Standard treatment for metastatic hormone positive (HR+) breast cancer includes a combination of a CDK4/6 inhibitor and antiestrogen therapy. Despite durable responses, eventual endocrine resistance results in disease progression. The Src/Abl pathway has been shown to mediate endocrine resistance in breast cancer, thus providing a promising target for novel therapies. Bosutinib is a tyrosine kinase inhibitor that targets the Src/Abl pathway, which has been studied in hematologic malignancies. Preclinical data suggests that the addition of bosutinib to a CDK4/6 inhibitor and antiestrogen therapy has the potential to reverse endocrine resistance. This is a phase I, single arm, open-label clinical trial in which we evaluate the combination of palbociclib and fulvestrant with bosutinib in metastatic HR+ breast cancer. Patients with confirmed advanced HR+/HER2- breast cancer who have received no more than three lines of chemotherapy and have progressed on at least one aromatase inhibitor and one CDK4/6 inhibitor will be enrolled. Participants will be given a combination of palbociclib, fulvestrant and bosutinib over 28-day cycles. The primary objective of this study is to assess the safety and tolerability of bosutinib in combination with palbociclib and fulvestrant in the study population. Secondary objectives are to 1) determine the anti-tumor effect of this therapeutic combination by assessing overall response rate (ORR) and clinical benefit rate (CBR) after 6 months of treatment, 2) to determine the clinical pharmacology parameters of bosutinib in this regimen, and 3) to build a tissue repository at Georgetown Lombardi Comprehensive Cancer Center for further translational study.

1 August 1994 in Gynecologic Oncology
Verified
Journal Article
Closed access
OTOssama Tawfik
Ossama Tawfik
MHManop Huntrakoon
Manop Huntrakoon
JCJulie Collins
Julie Collins
TOThaira Owiety
Thaira Owiety
MSMuhieddine A-F. Seoud
Muhieddine A-F. Seoud
JWJohn Weed
John Weed